Drug Development & Delivery Insights 2025

Cutting-edge drugs that lead the way in the marketplace are truly exceptional, but what sets manufacturers apart is their creativity and ingenuity in both discovering new methods and delivering these breakthroughs to patients. As market demands evolve and patient needs shift, we are witnessing a transformative shift in the types of drugs being developed and how they are administered.

This panel discussion offers a unique opportunity to delve into the exciting world of research and development, exploring the journey from the initial concept to delivery. Join us for an enlightening conversation with industry experts who are driving innovation forward, as we explore the dynamic trends that are shaping the future of this constantly evolving field.

C-Suite perspective from a leading CDMO with strong positions in oral, sterile and advanced biologics delivery as well as the biggest European CDMO footprint. We will touch on topics such as development challenges, European perspectives, advanced therapies landscape and predictive systems.

Timelines to bring NCEs to the clinic and ultimately to market continue to accelerate, requiring CMC teams to develop robust & scalable formulations prior to FiH studies. Fit-for-purpose phase I formulation result in expensive & time-consuming reformulation efforts that slow development and often do not address delivery challenges common to low solubility & low permeability development candidates. In this fireside chat, Rod Kertner, CCO of Serán Bioscience will discuss the challenges surrounding drug development of low solubility and low permeability candidates and provide an insight into a combination approach that can improve efficiencies.

Small molecules are the cornerstone of drug discovery. With the evolution of innovation in drug development, there is an increase in the possibilities in addressing complex diseases including autoimmune disorders, cancer, and cardiovascular conditions.

This executive interview, with BPGbio President and CEO Niven Narain, will dive into how technological advances have pushed for new methods of drug development. We will take a look at the intersection between biology and AI to discover not only how technology and innovation are advancing and creating new opportunities but also spurring on the discovery of how patients react to potential drugs, creating  commercial viability and much more. Don't miss this exciting interview with one of biotech's leading voices in the AI and biologics space.

This presentation will explore how tailored release technologies can be used to achieve clinically optimized, patient-centric outcomes. Moving beyond traditional modified release strategies, new approaches now integrate timing, rate control, site targeting, and stimuli responsiveness to better align drug profiles with disease biology, circadian rhythms, and patient needs. Through clinical use cases and emerging formulation strategies, we will demonstrate how tailored release profiles are redefining therapeutic precision across key disease areas.

Learning Objectives

1. Understand the classification and purpose of various tailored release systems, including time-controlled, rate-controlled, site-specific, and pulsatile delivery.
2. Recognize how these technologies can be applied in clinical settings to enhance efficacy, safety, and adherence across therapeutic areas.
3. Explore innovative approaches such as multiparticulates, chronotherapeutic platforms, and stimuli-responsive systems driving the next generation of drug delivery.

Learn how Medpharm’s proprietary human living skin models, which can be sustained for up to 30 days, are revolutionizing topical drug development and delivering more predictive and clinically relevant data.

The path to successful new drug development is increasingly complex, marked by scientific challenges, diverse regulatory requirements, and constrained resources—pressures felt especially acutely by start-up biotech companies. Drawing on experience from thousands of early-phase projects, this presentation will explore critical considerations for early-phase API and formulation R&D from a CDMO perspective. We will highlight key strategies to streamline development processes, optimize resource utilization, and accelerate the transition from discovery to development, ultimately enabling faster and more efficient IND filings.

From oncology treatment to obesity, how drugs are delivered is taking more and more of the marketplace as providers and, most importantly, patients are being faced with more options. Personalized medicine has the ability to meet patients where they are, meet culturally sensitive needs and the desires of patients who are receiving care in their homes or are unable to easily travel.

This executive interview will examine how manufacturers are addressing these demands from patients and how new and novel delivery methods are helping meet patient demands. Personalized, or precision, medicine isn't going away and as patient needs continue to grow, so must pharma.